PTCL Clinical Trials

2 recruiting

PTCL Trials at a Glance

13 actively recruiting trials for ptcl are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Créteil, Pierre-Bénite, and Lille. Lead sponsors running ptcl studies include Genfleet Therapeutics (Shanghai) Inc., Haihe Biopharma Co., Ltd., and AstraZeneca.

Browse ptcl trials by phase

Treatments under study

About PTCL Clinical Trials

Looking for clinical trials for PTCL? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PTCL trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PTCL clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 1Phase 2

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

Hodgkin LymphomaNon-Hodgkin LymphomaLymphoma+4 more
AstraZeneca161 enrolled33 locationsNCT06137144
Recruiting
Phase 1Phase 2

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

Peripheral T Cells Lymphoma (PTCL)
The Lymphoma Academic Research Organisation49 enrolled20 locationsNCT07018752
Recruiting
Phase 1Phase 2

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Haihe Biopharma Co., Ltd.100 enrolled1 locationNCT06909877
Recruiting
Phase 2

Phase II Clinical Trial of Drug Combinations Guided by Ex-vivo Testing in Patients With Relapsed/Refractory T-cell Lymphoma (COMBINEX-T)

Relapsed/Refractory Peripheral T-cell Lymphoma (RR PTCL)
National University Hospital Singapore36 enrolled1 locationACTRN12626000088347
Recruiting
Phase 2

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

PTCL
University of Virginia50 enrolled6 locationsNCT04747236
Recruiting
Phase 2

Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL

Peripheral T Cells Lymphoma (PTCL)
The First Affiliated Hospital of Soochow University26 enrolled1 locationNCT07372352
Recruiting
Phase 3

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.130 enrolled1 locationNCT06122389
Recruiting
Early Phase 1

Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma

DLBCLNK/T-cell LymphomaPeripheral T-cell Lymphoma (PTCL)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine24 enrolled1 locationNCT07162012
Recruiting
Phase 1

To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL

CD7 Positive R/R PTCL
Peking University People's Hospital18 enrolled1 locationNCT07143929
Recruiting
Phase 1Phase 2

Polyspecific Antibodies in Lymphoproliferative T-cell Disorders

Peripheral T Cells Lymphoma (PTCL)
Xenothera SAS54 enrolled8 locationsNCT06495723
Recruiting
Phase 1Phase 2

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Sun Yat-sen University33 enrolled1 locationNCT06855823
Recruiting
Phase 1Phase 2

A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Genfleet Therapeutics (Shanghai) Inc.95 enrolled1 locationNCT05934513
Recruiting

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

PTCL
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT05967949